Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- PMID: 27717299
- DOI: 10.1056/NEJMoa1611310
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Abstract
Background: Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer.
Methods: In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2:1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival.
Results: Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P<0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications.
Conclusions: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274 .).
Comment in
-
Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated disease.Nat Rev Clin Oncol. 2017 Feb;14(2):71. doi: 10.1038/nrclinonc.2016.207. Epub 2016 Dec 13. Nat Rev Clin Oncol. 2017. PMID: 27958296 No abstract available.
-
PARP Inhibitors in Ovarian Cancer Treatment.N Engl J Med. 2016 Dec 1;375(22):2197-2198. doi: 10.1056/NEJMe1612843. N Engl J Med. 2016. PMID: 27959768 No abstract available.
-
Niraparib in Recurrent Ovarian Cancer.N Engl J Med. 2017 Feb 23;376(8):801. doi: 10.1056/NEJMc1616633. N Engl J Med. 2017. PMID: 28229583 No abstract available.
Similar articles
-
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562799 Clinical Trial.
-
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17. Lancet Oncol. 2018. PMID: 30026000 Clinical Trial.
-
Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.Lancet Oncol. 2019 Oct;20(10):1409-1419. doi: 10.1016/S1470-2045(19)30515-7. Epub 2019 Aug 29. Lancet Oncol. 2019. PMID: 31474354 Clinical Trial.
-
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Ann Pharmacother. 2020 Oct;54(10):1010-1015. doi: 10.1177/1060028020912749. Epub 2020 Mar 16. Ann Pharmacother. 2020. PMID: 32172572 Review.
-
Niraparib: A Review in Ovarian Cancer.Target Oncol. 2018 Aug;13(4):533-539. doi: 10.1007/s11523-018-0582-1. Target Oncol. 2018. PMID: 30073633 Review.
Cited by
-
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP.J Pathol Transl Med. 2024 Jul;58(4):147-164. doi: 10.4132/jptm.2023.11.01. Epub 2024 Jan 10. J Pathol Transl Med. 2024. PMID: 39026440 Free PMC article. Review.
-
The microRNA Let-7 and its exosomal form: Epigenetic regulators of gynecological cancers.Cell Biol Toxicol. 2024 Jun 5;40(1):42. doi: 10.1007/s10565-024-09884-3. Cell Biol Toxicol. 2024. PMID: 38836981 Free PMC article. Review.
-
Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer.Sci Rep. 2024 Jun 1;14(1):12595. doi: 10.1038/s41598-024-63600-z. Sci Rep. 2024. PMID: 38824213 Free PMC article.
-
PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation.Front Oncol. 2024 May 14;14:1380633. doi: 10.3389/fonc.2024.1380633. eCollection 2024. Front Oncol. 2024. PMID: 38807759 Free PMC article.
-
Prognostic impact of suspicious extraabdominal lymph nodes on patient survival in advanced ovarian cancer.PLoS One. 2024 May 28;19(5):e0299205. doi: 10.1371/journal.pone.0299205. eCollection 2024. PLoS One. 2024. PMID: 38805507 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical